Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Novoeight® Phase 3 Data Show Reduction in Annualised Bleeding Rate Over Time in People With Haemophilia A

PR Newswire December 7, 2014

Glenn Foundation for Medical Research welcomes Dr. Kevin Lee as Senior Advisor

PR Newswire December 7, 2014

New Strategies Boost Healthy Red Blood Cell Production To Target Anemia Across A Range Of Blood Disorders

PR Newswire December 7, 2014

MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting

Thomson Reuters ONE December 6, 2014

MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting

PR Newswire December 6, 2014

Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma

GlobeNewswire December 6, 2014

IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma

PR Newswire December 6, 2014

Benefits Persist in T Cell Therapy for Children with Relapsed Leukemia

PR Newswire December 6, 2014

Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia

PR Newswire December 6, 2014

Merck Announces Positive Data Investigating the Use of Pembrolizumab in Patients with Classical Hodgkin Lymphoma at ASH Annual Meeting

Canada NewsWire December 6, 2014

Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia

Thomson Reuters ONE December 6, 2014

Novel Strategies Direct Immune System To Attack Recurrent, Hard-to-Treat Blood Cancers

PR Newswire December 6, 2014

Amgen Announces New Data From Phase 2 BLINCYTO(TM) (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease

PR Newswire December 6, 2014

Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood

GlobeNewswire December 6, 2014

Advances In Lymphoma And Multiple Myeloma Treatment Seek To Improve Outcomes For Patients With Hard-to-Treat Disease

PR Newswire December 6, 2014

Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma

PR Newswire December 6, 2014

Basal Cell Carcinoma (Epithelioma) Therapeutic Pipeline H2 2014 Review Research Report

PR Newswire December 6, 2014

Promising compound rapidly eliminates malaria parasite

PR Newswire December 5, 2014

Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients With Acute Myeloid Leukemia at the 2014 American Society of Hematology Annual Meeting

GlobeNewswire December 5, 2014

Cellular Biomedicine Group Releases Positive 48-Week Data From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)

GlobeNewswire December 5, 2014